Open Mon 8:30am : 01582 842096
FREE DELIVERY on most orders over £29
VioVet Insurance

NexGard Spectra

  • 2-3.5kg Extra Small Dog Chewable Tablet » Pack of 3 £16.28
  • 3.5-7.5kg Small Dog Chewable Tablet » Pack of 3 £18.59
  • 7.5-15kg Medium Dog Chewable Tablet » Pack of 3 £22.05
  • 15-30kg Large Dog Chewable Tablet » Pack of 3 £25.16
  • 30-60kg Extra Large Dog Chewable Tablet » Pack of 3 £29.06

Selection of 5 products from

£16.28 to £29.06

Description

NexGard Spectra is supplied in the form of a chewable, beef-flavoured tablet to be given once per month to dogs. It controls fleas, ticks, heartworm and gastro-intestinal roundworms. This is a very wide range of major parasites to be controlled safely and effectively with simple once monthly dosing.

Qualitative and quantitative composition

Active substance:

Each chewable tablet contains:

NexGard Spectra chewable tablets for dogs

Afoxolaner (mg)

Milbemycin Oxime (mg)

2–3.5 kg

9.375

1.875

>3.5–7.5 kg

18.75

3.75

>7.5–15 kg

37.50

7.5

>15–30 kg

75

15

>30–60 kg

150

30

For the full list of excipients, see below.

Pharmaceutical form

Mottled red to reddish brown circular shaped (for dogs 2–3.5 kg) or rectangular shaped (for dogs >3.5–7.5 kg, >7.5–15 kg, >15–30 kg and >30‑60 kg) chewable tablets.

Clinical particulars

Target species

Dogs

Indications for use

Treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease and/or treatment of gastrointestinal nematode infestations is indicated.

Treatment of flea infestations (Ctenocephalides felis and C. canis) in dogs for 5 weeks.

Treatment of tick infestations (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus) in dogs for 4 weeks.

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Ancylostoma braziliense) and whipworm (Trichuris vulpis).

Prevention of heartworm disease (Dirofilaria immitis larvae) with monthly administration.

Contra-indications

Do not use in case of hypersensitivity to the active substances or to any of the excipients.

Special warnings for each target species

Fleas and ticks need to start feeding on the host to become exposed to afoxolaner; therefore the risk of the transmission of vector-borne diseases cannot be excluded.

Parasite resistance to any particular class of parasiticides may develop following the frequent, repeated use of a product of that class. Therefore, the use of this product should be based on the assessment of each individual case and on local epidemiological information about the current susceptibility of the target species in order to limit the possibility of a future selection for resistance.

Maintenance of the efficacy of macrocyclic lactones is critical for Dirofilaria immitis control. To minimise the risk of resistance selection, it is recommended that dogs should be checked for both circulating antigens and blood microfilariae at the beginning of each season of preventative treatment. Only negative animals should be treated.

Special precautions for use in animals

In the absence of available data, treatment of puppies less than 8 weeks of age and dogs less than 2 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.

In heartworm endemic areas, dogs should be tested for existing heartworm infestation prior to administration of NexGard Spectra. At the discretion of the veterinarian, infested dogs should be treated with an adulticide to remove adult heartworms. NexGard Spectra is not indicated for microfilariae clearance. The recommended dose should be strictly observed in collies or related breeds.

Special precautions to be taken by the person administering the product to animals

-This product may cause gastrointestinal disturbances if ingested.

-Keep tablets in the blister packs until required, and keep the blisters in the outer carton.

-In case of accidental ingestion, particularly in the case of children, seek medical advice immediately and show the package leaflet or the label to the physician.

-Wash hands after use.

Adverse reactions

In clinical studies, no serious adverse reactions were attributed to the combination of afoxolaner and milbemycin oxime. Adverse reactions such as vomiting, diarrhoea, lethargy, anorexia, and pruritus were uncommonly observed. These occurrences were generally self-limiting and of short duration.

Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in breeding dogs. Use only according to the benefit-risk assessment by the responsible veterinarian.

Interactions

Milbemycin oxime is a substrate for P-glycoprotein (P-gp) and therefore could interact with other P-gp substrates (for example, digoxin, doxorubicin) or other macrocyclic lactones. Therefore, concomitant treatment with other P-gp substrates could lead to enhanced toxicity.

Amounts to be administered and administration route

For oral use.

Dose: The product should be administered at a dose of 2.50–5.36 mg/kg bodyweight of afoxolaner and 0.50–1.07 mg/kg bodyweight of milbemycin oxime in accordance with the following table:

Weight (kg)

Dosage

2 - 3.5

1 x NexGard Spectra (XS) 9 mg/2 mg tablet

> 3.5 - 7.5

1 x NexGard Spectra (S) 19 mg/4 mg tablet

>7.5 - 15

1 x NexGard Spectra (M) 38 mg/8 mg tablet

>15 - 30

1 x NexGard Spectra (L) 75 mg/15 mg tablet

>30 - 60

1 x NexGard Spectra (XL) 150 mg/30 mg tablet

For dogs above 60 kg appropriate combinations of chewable tablets should be used.

Method of administration: The tablets are chewable and palatable to most dogs. If the dog does not accept the tablets directly they may be administered with food.

Treatment schedule: The treatment schedule should be based on veterinary diagnosis and on the local epidemiological situation. NexGard Spectra can be used as part of the seasonal treatment of fleas and ticks (replacing treatment with a monovalent flea and tick product) in dogs with diagnosed concurrent gastrointestinal nematode infestations. A single treatment is effective for the treatment of gastrointestinal nematodes. After treatment of the nematode infestations, further flea and tick treatment should be continued with a monovalent product.

Heartworm disease: NexGard Spectra kills Dirofilaria immitis larvae up to one month after their transmission by mosquitoes therefore the product should be administered at regular monthly intervals during the time of the year when vectors are present, starting in the month after the first expected exposure to mosquitoes. Treatment should continue until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with NexGard Spectra should start on the date when the former medication was due to have been administered.

Dogs living in heartworm endemic areas, or those which have travelled to endemic areas, may be infested with adult heartworms. No therapeutic effect against adult Dirofilaria immitis has been established. It is therefore recommended that all dogs 8 months of age or more, living in heartworm endemic areas, should be tested for existing adult heartworm infestation before being treated with the product for heartworm prevention.

Overdose

No adverse reactions were observed in eight-week old healthy puppies after 6 treatments at up to 5 times the maximum dose.

Pharmacological particulars

Pharmacodynamic properties

Afoxolaner:

Afoxolaner is an insecticide and acaricide of the isoxazoline family. Afoxolaner acts as an antagonist at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA). Isoxazolines, among the chloride channel modulators, bind to a distinct and unique target site within the insect GABACls, thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. Prolonged afoxolaner-induced hyperexcitation results in uncontrolled activity of the central nervous system and death of insects and acarines. The selective toxicity of afoxolaner between insects, acarines and mammals may be inferred by the differential sensitivity of the insects and acarines’ GABA receptors versus mammalian GABA receptors.

It is active against adult fleas as well as against several tick species such as Rhipicephalus sanguineus, Dermacentor reticulatus and D. variabilis, Ixodes ricinus and I. scapularis, Amblyomma americanum, and Haemaphysalis longicornis.

Afoxolaner kills fleas before egg production and therefore prevents the risk of household contamination. It can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Milbemycin oxime:

Milbemycin oxime is an antiparasitic endectocide belonging to the group of macrocyclic lactones. Milbemycin oxime contains two major factors, A3 and A4 (ratio of 20:80 for A3:A4). It is a fermentation product of Streptomyces milbemycinicus. Milbemycin oxime acts by disrupting the glutamate neuro-transmission in invertebrates. Milbemycin oxime increases glutamate binding with consequent enhanced chloride ion flow into the cell. This leads to hyperpolarisation of the neuromuscular membrane resulting in paralysis and death of the parasites.

Pharmaceutical particulars

Excipients

Maize starch, Soy protein, Braised beef flavouring, Povidone (E1201), Macrogol 400, Macrogol 4000, Macrogol 15 hydroxystearate, Glycerol (E422), Medium-chain triglycerides, Citric acid monohydrate (E330), Butyl-hydroxytoluene (E321).

Major incompatibilities

Not applicable.

Shelf life

Shelf life of the product as packaged for sale: 2 years.

Special precautions for storage

Keep the blister in the outer carton in order to protect from light.

Immediate packaging

The product is individually packaged in plastic blisters. One carton contains one blister of 1, 3 or 6 chewable tablets. Not all pack sizes may be marketed.

Disposal

Any unused product or waste materials derived from it should be disposed of in accordance with local requirements.

Marketing authorisation number

EU/2/14/177/001-015.

Legal category

POM-V

GTIN (Global Trade Item No)

NexGard Spectra Dog (XS) x 3

03661103048572

NexGard Spectra Dog (XS) x 6

03661103048480

NexGard Spectra Dog (S) x 3

03661103048589

NexGard Spectra Dog (S) x 6

03661103048497

NexGard Spectra Dog (M) x 3

03661103048596

NexGard Spectra Dog (M) x 6

03661103048503

NexGard Spectra Dog (L) x 3

03661103048602

NexGard Spectra Dog (L) x 6

03661103048510

NexGard Spectra Dog (XL) x 3

03661103048619

NexGard Spectra Dog (XL) x 6

03661103048527

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Freephone*: 0800 084 2608
  • Mon - Fri: 8:30am - 6:00pm
  • Sat: 9:00am - 1:00pm
  • Email: support@viovet.co.uk

All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.

Questions & Answers for NexGard Spectra

Below are some recent questions we've received regarding NexGard Spectra, including answers from our team.

Ask Your Own Question

Is it 2 in 1?

18th Dec 2015
Myrto Geranopoulou
  • VioVet Customer Since: October 2012
  • From: ATTICA, Greece

My dog is 16,5 kg.
Do I give him a chewable NexGard Spectra, instead of a pipette once a month and a Drontal once every 3 months?

John Cousins
  • Veterinary Surgeon

Yes this would be good, though theoretically you only need to give a Droncit, not a Drontal, every 3 months. (Droncit is just for tapeworms and that is all you need along with NexGard. Drontal has an extra ingredient to control roundworms, which are covered by the NexGard anyway.) It would be safe enough either way, but ideally you avoid giving unnecessary medication.